Anti-CD79 antibody induces B cell anergy that protects against autoimmunity

J Immunol. 2014 Feb 15;192(4):1641-50. doi: 10.4049/jimmunol.1302672. Epub 2014 Jan 17.


B cells play a major role in the pathogenesis of many autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type I diabetes mellitus, as indicated by the efficacy of B cell-targeted therapies in these diseases. Therapeutic effects of the most commonly used B cell-targeted therapy, anti-CD20 mAb, are contingent upon long-term depletion of peripheral B cells. In this article, we describe an alternative approach involving the targeting of CD79, the transducer subunit of the B cell AgR. Unlike anti-CD20 mAbs, the protective effects of CD79-targeted mAbs do not require cell depletion; rather, they act by inducing an anergic-like state. Thus, we describe a novel B cell-targeted approach predicated on the induction of B cell anergy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Autoimmune Diseases / prevention & control*
  • Autoimmunity / immunology
  • B-Lymphocytes / immunology*
  • CD79 Antigens / immunology*
  • Clonal Anergy / immunology*
  • Female
  • Lymphocyte Activation / immunology
  • Lymphocyte Count
  • Lymphocyte Depletion
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Mice, Knockout


  • Antibodies, Monoclonal
  • CD79 Antigens